Abstract
Background: Large platelets are shown to be hemostatically more active. It has been suggested that mean platelet volume (MPV) is increased during acute myocardial infarction (AMI) and unstable angina pectoris (USAP). However, the underlying mechanism of the phenomenon remains unclear.
Methods: Twenty patients with AMI and 20 patients with USAP were included in this study. Seventeen healthy adult subjects served as controls. Venous blood samples of the subjects were drawn within 12 h after admission. Thrombopoietin levels were measured by ELISA and platelet counts and MPV were assayed by autoanalyzer.
Results: Patients with AMI and USAP had higher platelet counts than those in the control group. Although the platelet counts were slightly higher in AMI than in USAP, this did not reach statistical significance. Mean platelet volume and levels of TP were found to be elevated in patients with AMI and USAP compared with control subjects (p < 0.001). Thrombopoietin levels were higher in AMI than USAP, but this was not statistically significant. There was a positive correlation between TP levels and MPV values (p < 0.05).
Conclusion: Increased TP levels may increase both platelet counts and platelet size, resulting in hemostatically more active platelets, which may contribute to the development and progression of CAD.
Keywords: thrombopoietin, mean platelet volume, platelets, coronary artery disease
Full Text
The Full Text of this article is available as a PDF (443.4 KB).
REFERENCES
- 1. Kaushansky K: Thrombopoietin: The primary regulator of platelet production. Blood 1995; 86: 419–431 [PubMed] [Google Scholar]
- 2. Long MW, Hoffman R: Thrombocytopoiesis In Haematology: Basic Principles and Practice (Eds. Hofman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ.) p. 245–259. New York: Churchill Livingstone, 2000. [Google Scholar]
- 3. Ross R: The pathogenesis atherosclerosis: A perspective for the 1990's. Nature 1993; 62: 801–809 [DOI] [PubMed] [Google Scholar]
- 4. Martin JF, Trowbridge EA, Salmon GL, Slater DN: The relationship between platelet and megakaryocyte volumes. Thromb Res 1982; 287: 456–459 [DOI] [PubMed] [Google Scholar]
- 5. Kristensen SD, Roberts KM, Kishk YT, Martin JF: Accelerated atherogenesis occurs following platelet destruction and increases in megakaryocyte size and DNA content. Eur J Clin Invest 1990; 220: 239–247 [DOI] [PubMed] [Google Scholar]
- 6. Nurden P, Paujol C, Nurden AT: The evaluation of megakaryocytes to platelets In Baillère's Clinical Hematology. Megakaryocytes and Platelet Disorders (Eds. Caen JP, Han ZC.), p. 1–29. London: W.B.Saunders Co., 1997. [Google Scholar]
- 7. Pizzulli L, Yang A, Martin JF, Luderitz B: Changes in platelet size and count in unstable angina compared to stable angina or non‐cardiac chest pain. Cor Art Dis 1995; 6 (5): 397–402 [DOI] [PubMed] [Google Scholar]
- 8. Halbmayer WM, Haushofer A, Radek J, Schon R, Deutsch M, Fischer M: Platelet size, fibrinogen and lipoprotein(a) in coronary heart disease. Eur Heart J 1998; 19 (1): 80–84 [DOI] [PubMed] [Google Scholar]
- 9. Borne VDM, Folman C, Linthorst GE, Porcelijn Oudenrijn SVD, Schoot EVD: Thrombopoietin and its receptor: Structure, function and role in the regulation of platelet production In Baillère's Clinical Haematology. Megakaryocytes and Platelet Disorders (Eds. Caen JP, Han ZC.), p. 209–427. London: W.B. Saunders Co., 1998. [DOI] [PubMed] [Google Scholar]
- 10. Bruce RA: Exercise testing of patients with coronary heart disease: Principles and normal standards for evaluation. Ann Clin Res 1971; 3: 323–332 [PubMed] [Google Scholar]
- 11. Threatte GA: Mean platelet volume: The need for a reference method. Am J Clin Pathol 1984; 81: 769–772 [DOI] [PubMed] [Google Scholar]
- 12. Trowbridge EA, Martin JF: The platelet volume distribution: A signature of the pre‐thrombotic state in coronary artery disease?. Thromb Haemost 1987; 58: 514–518 [PubMed] [Google Scholar]
- 13. Martin JF, Bath PMW, Burr ML: Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338: 1409–1411 [DOI] [PubMed] [Google Scholar]
- 14. Rodgers GM, Bithell TC: The diagnostic approach to the bleeding disorders In Wintrobe's Clinical Haematology (Eds. Lee GR, Foerster J, Lukens J, Paraskev F, Greer JP, Rodgers GM.), p. 1157–1578. Egypt: Williams and Wilkins, 1999. [Google Scholar]
- 15. Smyth DW, Martin JF, Michalis L, Bucknall CA, Jewitt DE: Influence of platelet size before coronary angioplasty on subsequent restenosis. Eur J Clin Invest 1993; 23 (6): 361–367 [DOI] [PubMed] [Google Scholar]
- 16. Martin JF, Plumb J, Kilbey RS, Kiskh YT: Changes in volume and density of platelets and its relationship to volume. Br Med J 1983; 287: 456–459 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Giles H, Smith REA, Martin JF: Platelet glycoprotein IIb‐IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest 1994; 24: 69–72 [DOI] [PubMed] [Google Scholar]
- 18. Wendling F, Han ZC: Positive and negative regulation of megakaryocytopoiesis In Baillère's Clinical Haematology. Megakaryocytes and Platelet Disorders (Eds. Caen JP, Han ZC.), p. 29–45. London: W.B. Saunders Co., 1998. [DOI] [PubMed] [Google Scholar]
- 19. Stahl CP, Zucker FD, Evatt BL, Winton EF: Effects of human interleukin‐6 on megakaryocyte development and thrombocytopoiesis in primates. Blood 1991; 78: 1467–1475 [PubMed] [Google Scholar]
- 20. Caen JP, Han ZC: Megakaryocyte differentiation: Positive and negative regulation. Cell Res 1995; 5: 23–31 [Google Scholar]
- 21. Haznedaroǧlu IC, Güllü IH, Dündar SV, Kirazli Ş: The significance and distinct interactions of various growth factors in physiological and pathological megakaryocytopoiesis/thrombocytopoiesis. Aust NZ J Med 1997; 27: 191–192 [DOI] [PubMed] [Google Scholar]
- 22. Eaton DL, de Sauvage FJ: Thrombopoietin: The primary regulator of megakaryocytopoiesis and thrombocytopoiesis. Exp Hematol 1997; 25: 1–7 [PubMed] [Google Scholar]
- 23. de Sauvage FJ, Carver‐Moore K, Luoh SM, Ryan A, Dowd M, Eaton DL, Moore MW: Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996; 183: 651–656 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Cohen‐Solal K, Villeval JL, Titeux M, Lok S, Vainchenker W, Wendling F: Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 1996; 88: 2578–2584 [PubMed] [Google Scholar]
- 25. Emmons RVB, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR: Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87: 4068–4071 [PubMed] [Google Scholar]
- 26. Stoffel R, Wiestner A, Skoda RC: Thrombopoietin in thrombocytopenic mice: Evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996; 87: 567–573 [PubMed] [Google Scholar]
- 27. Eaton DL, de Sauvage FJ: Thrombopoietin: The primary regulator of megakaryocytopoiesis and thrombocytopoiesis. Exp Hematol 1997; 25: 1–7 [PubMed] [Google Scholar]
- 28. Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver‐ Moore K, de Sauvage FJ: Regulation of thrombopoietin levels by c‐mpl‐mediated binding to platelets. Blood 1996, 87: 2154–2161 [PubMed] [Google Scholar]
- 29. McCartey JM, Sprugel KH, Fox NE: Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995; 86: 3668–3675 [PubMed] [Google Scholar]
- 30. Fielder PJ, Hass P, Nagel M: Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997; 89: 2782–2788 [PubMed] [Google Scholar]
- 31. Sinzinger H, Virgolini I, Fitscha P: Platelet kinetics in patients with atherosclerosis. Thromb Res 1990; 57: 507–516 [DOI] [PubMed] [Google Scholar]